stockrowDenali Therapeutics Inc.
DNLI Healthcare Biotechnology
Denali Therapeutics Inc.’s revenue for fiscal 2023 (year ended December 2023) was $330.5 million, up 204.7% from fiscal 2022.
- Revenue
- −94.0%
- EPS
- +150.3%
- Free cash flow
- −11.8%
- Total debt
- −1.89%
Quarter to September 2026, against a year earlier
Follow DNLI
Alert me
Denali Therapeutics Inc. (DNLI) Free cash flow margin
Denali Therapeutics Inc.'s free cash flow margin over the twelve months to 30 September 2026 was −1,986.8%, down 1986.8 percentage points from fiscal 2025 (0.00%). Over the past ten years it has ranged from −635.3% (fiscal 2019) to 123.1% (fiscal 2020); the current reading is higher than 82% of that period. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | 112.22 |
| FY2023 | −112.2% | 129.84 |
| FY2022 | −242.1% | 209.82 |
| FY2021 | −451.9% | (574.94) |
| FY2020 | 123.1% | 758.40 |
| FY2019 | −635.3% | (671.51) |
| FY2018 | 36.2% | 36.17 |
| FY2017 | 0.00% | 0.00 |
| FY2016 | 0.00% | 0.00 |
Against its own ten years
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| TARS Tarsus Pharmaceuticals, Inc. compare | 4.76% |
| ELVN Enliven Therapeutics, Inc. compare | 0.00% |
| DYN Dyne Therapeutics, Inc. compare | 0.00% |
| CELC Celcuity, Inc. compare | 0.00% |
| TLX Telix Pharmaceuticals Limited compare | 0.00% |
| VKTX Viking Therapeutics, Inc. compare | 0.00% |
| IDYA IDEAYA Biosciences, Inc. compare | −957.4% |
| VRDN Viridian Therapeutics, Inc. compare | −1,305.4% |
| DNLI Denali Therapeutics Inc. | −1,986.8% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on DNLI
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement